Literature DB >> 26725739

Investigation of miscellaneous hERG inhibition in large diverse compound collection using automated patch-clamp assay.

Hai-bo Yu1, Bei-yan Zou2,3, Xiao-liang Wang1, Min Li2,4.   

Abstract

AIM: hERG potassium channels display miscellaneous interactions with diverse chemical scaffolds. In this study we assessed the hERG inhibition in a large compound library of diverse chemical entities and provided data for better understanding of the mechanisms underlying promiscuity of hERG inhibition.
METHODS: Approximately 300 000 compounds contained in Molecular Library Small Molecular Repository (MLSMR) library were tested. Compound profiling was conducted on hERG-CHO cells using the automated patch-clamp platform-IonWorks Quattro(™).
RESULTS: The compound library was tested at 1 and 10 μmol/L. IC50 values were predicted using a modified 4-parameter logistic model. Inhibitor hits were binned into three groups based on their potency: high (IC50<1 μmol/L), intermediate (1 μmol/L< IC50<10 μmol/L), and low (IC50>10 μmol/L) with hit rates of 1.64%, 9.17% and 16.63%, respectively. Six physiochemical properties of each compound were acquired and calculated using ACD software to evaluate the correlation between hERG inhibition and the properties: hERG inhibition was positively correlative to the physiochemical properties ALogP, molecular weight and RTB, and negatively correlative to TPSA.
CONCLUSION: Based on a large diverse compound collection, this study provides experimental evidence to understand the promiscuity of hERG inhibition. This study further demonstrates that hERG liability compounds tend to be more hydrophobic, high-molecular, flexible and polarizable.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26725739      PMCID: PMC4722980          DOI: 10.1038/aps.2015.143

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  41 in total

Review 1.  Troubleshooting problems with in vitro screening of drugs for QT interval prolongation using HERG K+ channels expressed in mammalian cell lines and Xenopus oocytes.

Authors:  Harry J Witchel; James T Milnes; John S Mitcheson; Jules C Hancox
Journal:  J Pharmacol Toxicol Methods       Date:  2002 Sep-Oct       Impact factor: 1.950

2.  Prospective validation of a comprehensive in silico hERG model and its applications to commercial compound and drug databases.

Authors:  Munikumar R Doddareddy; Elisabeth C Klaasse; Adriaan P Ijzerman; Andreas Bender
Journal:  ChemMedChem       Date:  2010-05-03       Impact factor: 3.466

3.  Prediction of hERG K+ blocking potency: application of structural knowledge.

Authors:  A O Aptula; M T D Cronin
Journal:  SAR QSAR Environ Res       Date:  2004 Oct-Dec       Impact factor: 3.000

4.  Development and evaluation of an in silico model for hERG binding.

Authors:  Minghu Song; Matthew Clark
Journal:  J Chem Inf Model       Date:  2006 Jan-Feb       Impact factor: 4.956

Review 5.  Advancing Biological Understanding and Therapeutics Discovery with Small-Molecule Probes.

Authors:  Stuart L Schreiber; Joanne D Kotz; Min Li; Jeffrey Aubé; Christopher P Austin; John C Reed; Hugh Rosen; E Lucile White; Larry A Sklar; Craig W Lindsley; Benjamin R Alexander; Joshua A Bittker; Paul A Clemons; Andrea de Souza; Michael A Foley; Michelle Palmer; Alykhan F Shamji; Mathias J Wawer; Owen McManus; Meng Wu; Beiyan Zou; Haibo Yu; Jennifer E Golden; Frank J Schoenen; Anton Simeonov; Ajit Jadhav; Michael R Jackson; Anthony B Pinkerton; Thomas D Y Chung; Patrick R Griffin; Benjamin F Cravatt; Peter S Hodder; William R Roush; Edward Roberts; Dong-Hoon Chung; Colleen B Jonsson; James W Noah; William E Severson; Subramaniam Ananthan; Bruce Edwards; Tudor I Oprea; P Jeffrey Conn; Corey R Hopkins; Michael R Wood; Shaun R Stauffer; Kyle A Emmitte
Journal:  Cell       Date:  2015-06-04       Impact factor: 41.582

6.  ADMET evaluation in drug discovery. 12. Development of binary classification models for prediction of hERG potassium channel blockage.

Authors:  Sichao Wang; Youyong Li; Junmei Wang; Lei Chen; Liling Zhang; Huidong Yu; Tingjun Hou
Journal:  Mol Pharm       Date:  2012-03-16       Impact factor: 4.939

7.  Characterization of HERG potassium channel inhibition using CoMSiA 3D QSAR and homology modeling approaches.

Authors:  Robert A Pearlstein; Roy J Vaz; Jiesheng Kang; Xiao-Liang Chen; Maria Preobrazhenskaya; Andrey E Shchekotikhin; Alexander M Korolev; Ludmila N Lysenkova; Olga V Miroshnikova; James Hendrix; David Rampe
Journal:  Bioorg Med Chem Lett       Date:  2003-05-19       Impact factor: 2.823

Review 8.  hERG-related drug toxicity and models for predicting hERG liability and QT prolongation.

Authors:  Emanuel Raschi; Luisa Ceccarini; Fabrizio De Ponti; Maurizio Recanatini
Journal:  Expert Opin Drug Metab Toxicol       Date:  2009-09       Impact factor: 4.481

9.  Discovery of a series of 2-phenyl-N-(2-(pyrrolidin-1-yl)phenyl)acetamides as novel molecular switches that modulate modes of K(v)7.2 (KCNQ2) channel pharmacology: identification of (S)-2-phenyl-N-(2-(pyrrolidin-1-yl)phenyl)butanamide (ML252) as a potent, brain penetrant K(v)7.2 channel inhibitor.

Authors:  Yiu-Yin Cheung; Haibo Yu; Kaiping Xu; Beiyan Zou; Meng Wu; Owen B McManus; Min Li; Craig W Lindsley; Corey R Hopkins
Journal:  J Med Chem       Date:  2012-07-26       Impact factor: 7.446

10.  Global analysis reveals families of chemical motifs enriched for HERG inhibitors.

Authors:  Fang Du; Joseph J Babcock; Haibo Yu; Beiyan Zou; Min Li
Journal:  PLoS One       Date:  2015-02-20       Impact factor: 3.240

View more
  7 in total

1.  Ion channels research in the post-genomic era.

Authors:  Bernard Attali; Zhao-Bing Gao
Journal:  Acta Pharmacol Sin       Date:  2016-01       Impact factor: 6.150

2.  Compilation and physicochemical classification analysis of a diverse hERG inhibition database.

Authors:  Remigijus Didziapetris; Kiril Lanevskij
Journal:  J Comput Aided Mol Des       Date:  2016-10-25       Impact factor: 3.686

Review 3.  The High Cost of Stroke and Stroke Cytoprotection Research.

Authors:  Paul A Lapchak; John H Zhang
Journal:  Transl Stroke Res       Date:  2016-12-30       Impact factor: 6.829

4.  Discovery of Investigational Drug CT1812, an Antagonist of the Sigma-2 Receptor Complex for Alzheimer's Disease.

Authors:  Gilbert M Rishton; Gary C Look; Zhi-Jie Ni; Jason Zhang; Yingcai Wang; Yaodong Huang; Xiaodong Wu; Nicholas J Izzo; Kelsie M LaBarbera; Colleen S Limegrover; Courtney Rehak; Raymond Yurko; Susan M Catalano
Journal:  ACS Med Chem Lett       Date:  2021-08-09       Impact factor: 4.632

5.  A Pooled Analysis of Three Randomized Phase I/IIa Clinical Trials Confirms Absence of a Clinically Relevant Effect on the QTc Interval by Umibecestat.

Authors:  Stefan Viktor Vormfelde; Nicole Pezous; Gilbert Lefèvre; Carine Kolly; Ulf Neumann; Pierre Jordaan; Mike Ufer; Eric Legangneux
Journal:  Clin Transl Sci       Date:  2020-07-23       Impact factor: 4.689

6.  A structure-based computational workflow to predict liability and binding modes of small molecules to hERG.

Authors:  Subha Kalyaanamoorthy; Shawn M Lamothe; Xiaoqing Hou; Tae Chul Moon; Harley T Kurata; Michael Houghton; Khaled H Barakat
Journal:  Sci Rep       Date:  2020-10-01       Impact factor: 4.379

7.  The Effect of a Synthetic Estrogen, Ethinylestradiol, on the hERG Block by E-4031.

Authors:  Fumiya Tamura; Shintaro Sugimoto; Mana Sugimoto; Kazuho Sakamoto; Masahiko Yamaguchi; Takeshi Suzuki; Keiichi Fukuda; Masaki Ieda; Junko Kurokawa
Journal:  Biomolecules       Date:  2021-09-20
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.